FDA announces recall of more than 3,000 catheters after 9 serious injuries

The FDA has announced that Imperative Care is recalling multiple lots of its Zoom 71 reperfusion catheter, used to remove blood clots in stroke patients, due to a heightened risk that it could break during use.

“This could lead to fractured pieces left inside the patient’s bloodstream, resulting in serious adverse events such as blockage of blood vessels, stroke and death,” according to the FDA’s advisory.  

This is a Class I recall, meaning the use of this device “may cause serious injuries or death.” A total of nine serious injuries have been reported so far; there have been no deaths.

The recall includes 3,098 units distributed from September 2020 to August 2021. Imperative Care first alerted its customers back in August, asking them to “remove and quarantine all unused affected products.” These products can then be returned to Imperative Care, and the company pledged to help customers find a suitable replacement.

The full FDA advisory is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.